Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04238754 · ClinicalTrials.gov registry record · Phase 1
Oral Cannabidiol for Opioid Withdrawal
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04238754: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04238754 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04238754, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to support an R01 grant application to more closely examine this hypothesis.
Interventions
- DRUG Placebo
- DRUG Epidiolex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04238754
The ClinicalTrials.gov registry entry for NCT04238754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04238754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04238754 about?
NCT04238754 is a clinical study titled "Oral Cannabidiol for Opioid Withdrawal". This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to su...
What is the current status of trial NCT04238754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-11-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04238754?
The interventions under investigation include: Placebo (DRUG), Epidiolex (DRUG).
Who is sponsoring clinical trial NCT04238754?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.